Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase in Chronic Liver Disease and Cirrhosis-Related Deaths Marking These as Ninth Leading Cause of Death in U.S.
Salix Pharmaceuticals, the gastroenterology business of Bausch Health Companies Inc., has released the Salix Liver Health Trends Report, Third Edition, shedding light on the growing crisis of chronic liver disease (CLD). The report reveals a concerning 9% increase in CLD and cirrhosis mortality, making them the ninth leading cause of death in the United States in 2021.
Based on a survey of 400 healthcare providers (HCPs) who treat CLD, qualitative interviews with HCPs, and secondary research from peer-reviewed publications, the report highlights the ongoing disparities and gaps in CLD care that affect different populations and geographies. It also emphasizes the shortage of liver specialists in rural areas.
Nicola Kayel, Senior Vice President of Marketing at Salix, stated, “Over its first three editions, the Salix Liver Health Trends Report has described the enduring disparities and tremendous burden seen across the treatment of chronic liver disease. The report makes clear that increased education and awareness on the issues facing CLD care, as well as distinct and practical treatment guidelines, are vital tools to help healthcare providers improve CLD management and provide better experiences and outcomes for people living with CLD.”
The Salix Liver Health Trends Report, Third Edition provides comprehensive findings on the state of chronic liver disease and cirrhosis. It also offers healthcare provider resources to aid in the identification and management of patients with CLD and cirrhosis. The complete report can be accessed at LiverHealthNow.com.
Key findings from the report include:
1. Increase in CLD and cirrhosis mortality: The report reveals a 9% increase in CLD and cirrhosis mortality, making them the ninth leading cause of death in the United States in 2021.
2. Disparities in CLD care: The report highlights ongoing disparities and gaps in CLD care that affect different populations and geographies. It emphasizes the shortage of liver specialists in rural areas, leading to limited access to quality care.
3. Education and awareness: The report emphasizes the importance of increased education and awareness on the issues facing CLD care. It suggests that improved knowledge and understanding can lead to better management and outcomes for individuals living with CLD.
The Salix Liver Health Trends Report, Third Edition was compiled using an online survey, qualitative telephone interviews, and secondary research from peer-reviewed publications. The survey included 400 healthcare providers, representing gastroenterologists, hospital-based specialists, primary care physicians, and nurse practitioners/physician assistants.
Salix Pharmaceuticals, a subsidiary of Bausch Health Companies Inc., is dedicated to the management and treatment of gastrointestinal diseases. With over 30 years of experience, Salix has developed and marketed innovative products to improve patients’ lives and provide healthcare providers with effective solutions for chronic and debilitating conditions.
Bausch Health Companies Inc. is a global diversified pharmaceutical company committed to improving people’s lives with its healthcare products. The company focuses on various therapeutic areas, including gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health.
The release of the Salix Liver Health Trends Report, Third Edition underscores Salix’s commitment to raising awareness and knowledge of CLD and cirrhosis. By providing online resources and support, Salix aims to empower healthcare providers and improve patient outcomes.
For more information about Salix Pharmaceuticals and Bausch Health Companies Inc., visit their respective websites. Stay updated on their latest developments by following them on Twitter and LinkedIn.